Brokers Set Expectations for RIGL Q1 Earnings

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – Equities researchers at B. Riley issued their Q1 2025 earnings estimates for Rigel Pharmaceuticals in a research report issued on Tuesday, March 4th. B. Riley analyst K. Patel expects that the biotechnology company will post earnings of $0.10 per share for the quarter. B. Riley has a “Neutral” rating and a $24.00 price objective on the stock. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $0.22 per share. B. Riley also issued estimates for Rigel Pharmaceuticals’ Q2 2025 earnings at $0.18 EPS, Q3 2025 earnings at $0.17 EPS, Q4 2025 earnings at $0.38 EPS and FY2025 earnings at $0.84 EPS.

A number of other research analysts have also issued reports on RIGL. StockNews.com lowered Rigel Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. Piper Sandler increased their price objective on shares of Rigel Pharmaceuticals from $15.00 to $23.00 and gave the company a “neutral” rating in a report on Thursday, November 14th. Cantor Fitzgerald lifted their target price on shares of Rigel Pharmaceuticals from $15.00 to $25.00 and gave the company a “neutral” rating in a research report on Tuesday, December 10th. Citigroup upped their price target on shares of Rigel Pharmaceuticals from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, HC Wainwright reiterated a “buy” rating and issued a $57.00 price objective on shares of Rigel Pharmaceuticals in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $36.80.

Rigel Pharmaceuticals Trading Down 2.9 %

Shares of RIGL opened at $19.70 on Friday. The firm has a market cap of $347.02 million, a P/E ratio of 140.72 and a beta of 1.35. Rigel Pharmaceuticals has a 12 month low of $7.48 and a 12 month high of $29.82. The stock’s 50 day moving average is $20.09 and its two-hundred day moving average is $18.42.

Rigel Pharmaceuticals (NASDAQ:RIGL) last posted its earnings results on Tuesday, March 4th. The biotechnology company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.30 by $0.50. The firm had revenue of $57.60 million for the quarter, compared to analysts’ expectations of $57.59 million. Rigel Pharmaceuticals had a negative return on equity of 14.80% and a net margin of 2.46%.

Insiders Place Their Bets

In other news, CFO Dean L. Schorno sold 2,036 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $20.92, for a total value of $42,593.12. Following the transaction, the chief financial officer now directly owns 58,969 shares of the company’s stock, valued at approximately $1,233,631.48. This trade represents a 3.34 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Raul R. Rodriguez sold 4,952 shares of the company’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $20.92, for a total transaction of $103,595.84. Following the sale, the chief executive officer now directly owns 243,854 shares of the company’s stock, valued at approximately $5,101,425.68. This represents a 1.99 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 9,113 shares of company stock valued at $190,644 in the last 90 days. 9.04% of the stock is owned by insiders.

Institutional Investors Weigh In On Rigel Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Los Angeles Capital Management LLC boosted its stake in Rigel Pharmaceuticals by 34.5% during the third quarter. Los Angeles Capital Management LLC now owns 74,502 shares of the biotechnology company’s stock worth $1,205,000 after buying an additional 19,094 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Rigel Pharmaceuticals by 29.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 98,006 shares of the biotechnology company’s stock valued at $1,586,000 after acquiring an additional 22,443 shares during the last quarter. FMR LLC boosted its position in shares of Rigel Pharmaceuticals by 119.4% during the 3rd quarter. FMR LLC now owns 48,105 shares of the biotechnology company’s stock valued at $778,000 after acquiring an additional 26,184 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Rigel Pharmaceuticals by 1,199.2% in the third quarter. BNP Paribas Financial Markets now owns 21,008 shares of the biotechnology company’s stock valued at $340,000 after purchasing an additional 19,391 shares during the period. Finally, Stonepine Capital Management LLC increased its position in Rigel Pharmaceuticals by 1.3% during the third quarter. Stonepine Capital Management LLC now owns 309,100 shares of the biotechnology company’s stock worth $5,001,000 after purchasing an additional 4,100 shares during the last quarter. Institutional investors and hedge funds own 66.23% of the company’s stock.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.